A.M. Sikander: “We are expanding both organically and inorganically”

Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO

CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat…

Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO

Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies…

Our differentiation is validated by strong, sustainable unit economics: Prenetics CEO

Prenetics Global Limited (NASDAQ: PRE), headquartered in Hong Kong, is a health sciences company active…